Moderna CEO sees likely need for COVID booster for high-risk groups, eyes flu market
"Discussions now are really turning to 2022, and governments being worried about boosts," Stephane Bancel told Yahoo Finance.
finance.yahoo.com
Moderna is also pursuing a combination flu and COVID-19 vaccine, with trials set to start this year.
It's not the only company preparing to do so, as the messenger RNA platform is now being viewed more favorably during the pandemic.
The trajectory has set the stage for other products in the pipeline to move forward. That includes niche diseases, as well as a personalized cancer vaccine in partnership with Merck (MRK).
Regulatory authorities "did a lot of extraordinary things" for the COVID-19 vaccines, and Moderna will not rush approval for a vaccine in an already saturated market, the CEO said.
'스크랩 > 신문 기사' 카테고리의 다른 글
| U.K. to Offer Under-40s Alternative to AstraZeneca Covid Vaccine (0) | 2021.05.07 |
|---|---|
| UK reports four more COVID deaths - lowest rise since early September (0) | 2021.04.20 |
| 오세훈 "빠른 주택공급 실행계획 마련하라" (0) | 2021.04.13 |
| Covid-19: World's first human trials given green light in UK (0) | 2021.02.17 |
| [스크랩] Microsoft & PwC develop ZF’s digital manufacturing platform (0) | 2021.02.14 |